anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An implantable osmotically driven syringe is disclosed which can be used to deliver a beneficial agent, such as a drug, at a predetermined rate over an extended period of time. A movable piston divides the syringe into a beneficial agent-containing compartment and a driving compartment. The piston is movable into a position wherein the driving compartment has a volume of essentially zero. The syringe is driven by an osmotic engine which has a shaped wall surrounding, and in contact with, an osmotic solute. The wall is comprised of a semipermeable and/or microporous material which is permeable to the external fluid (e.g., water) but is impermeable to the solute. The engine also has a passageway forming a fluid flow path between the osmotic solute and the driving compartment. A portion of the wall is exposed to a fluid-containing external environment. At least about 30% of the wall which contacts the solute also is exposed to the fluid in the external environment. In operation, water from the external environment is imbided through the semipermeable wall forming a solution of the solvent in the osmotic engine. As fresh incoming fluid from the external environment is imbided by the engine, the solution is pumped through the passageway into the driving compartment. The pumping action drives the piston which causes the beneficial agent to be delivered by the syringe.
Participants received elagolix 150 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg QD for an additional 12 weeks.
PURPOSE:To obtain a solid pharmaceutical containing bile acid in a high concentration and having masked bitterness unique to the bile acid, by containing the bile acid and beta-cyclodextrin in a specific proportion. CONSTITUTION:A solid pharmaceutical of bile acid obtained by blending bile acid (ursodeoxycholic acid or chenodeoxycholic acid) with beta-cyclodextrin so as to provide 0.8-3.0wt. ratio of the beta-cyclodextrin to the bile acid and 250-550mg content of the bile acid in 1g pharmaceutical, then adding a binder, such as hydroxypropyl cellulose, and granulating the resultant blend. Tablets are prepared by tableting such powder or granule. Since this solid pharmaceutical contains the bile acid in a high concentration, the number of administration times can be reduced and the pharmaceutical is particularly effective in using as a gallstone dissolvent requiring administration of the bile acid in a high dose. Bitterness of the bile acid is completely masked and administration is readily carried out though the bile acid is in a unincluded state.
Sequential icotinib plus chemotherapy : pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
The aim of this study is to reveal the effect of motivational interviewing based on change stages on digital game addiction. This study will be conducted with a total of 72 individuals assigned by a randomization site from all nursing students who study at Sivas Cumhuriyet University, Faculty of Health Sciences, voluntarily participated in the study, and were found to be digital game addicts. These individuals will be equally distributed to the intervention and control groups. Each group will contain 36 participants. the participants in intervention group will take motivational interventions while the individuals who have digital game addiction in control group will not take this application. Personal Information Form, Stages of Change Questionnaire and Digital Game Addiction Scale will be distributed to individuals to answer. The obtained data will be analyzed statistically.
BACKGROUND: There are few molecular markers driving treatment selection in later lines of treatment for advanced colorectal cancer patients. The vast majority of patients who progress after first- and second-line therapy undergo chemotherapy regardless of molecular data.
OBJECTIVE: We aimed to assess the prognostic and predictive effects of specific RAS mutations on overall survival of patients receiving regorafenib (rego), trifluridine/tipiracil (TFD/TPI), or both.
PATIENTS AND METHODS: This was a retrospective observational study based on data from a previous study of our research network, involving nine Italian institutions over a 10-year timeframe (2012-2022). Extended RAS analysis, involving KRAS exon 2-4 and NRAS exon 2-4, and BRAF were the main criteria for inclusion in this retrospective evaluation. Patients with BRAF mutation were excluded. Patients were classified according to treatment (rego- or TFD/TPI-treated) and RAS mutational status (wild-type [WT], KRAS codon 12 mutations, KRAS codon 13 mutations, KRAS rare mutations and NRAS mutations, KRAS G12C mutation and KRAS G12D mutation).
RESULTS: Overall, 582 patients were included in the present analysis. Overall survival did not significantly differ in rego-treated patients according to RAS extended analysis, although a trend toward a better median survival in patients carrying G12D mutation (12.0 months), Codon 13 mutation (8.0 months), and Codon 12 mutation (7.0 months) has been observed, when compared with WT patients (6.0 months). Overall survival did not significantly differ in TFD/TPI-treated patients according to RAS extended analysis, although a trend toward a better median survival in WT patients had been observed (9.0 months) in comparison with the entire population (7.0 months). Patients receiving both drugs displayed a longer survival when compared with the population of patients receiving rego alone (p = 0.005) as well as the population receiving TFD/TPI alone (p < 0.001), suggesting a group enriched for favorable prognostic factors. However, when each group was analyzed separately, the addition of TFD/TPI therapy to the rego-treated group improved survival only in all-RAS WT patients (p = 0.003). Differently, the addition of rego therapy to TFD/TPI-treated patients significantly improved OS in the Codon 12 group (p = 0.0004), G12D group (p = 0.003), and the rare mutations group (p = 0.02), in addition to all-RAS WT patients (p = 0.002). The rego-TFD/TPI sequence, compared with the reverse sequence, significantly improved OS only in the KRAS codon 12 group (p = 0.003).
CONCLUSIONS: Our data demonstrate that RAS mutations do not affect outcome in rego-treated patients as well as TFD/TPI-treated patients. Nevertheless, a trend toward a higher efficacy of rego in RAS-mutated (in particular codon 12, rare RAS mutations, and G12D) patients has been recorded. The rego-TFD/TPI sequence seems to be superior to the reverse sequence in patients carrying an RAS codon 12 mutation, although the impact of other factors as disease burden or performance status cannot be excluded.
14.6% Sodium Chloride Injection, USP Additive Solution is a sterile, nonpyrogenic, concentrated solution for intravenous administration ONLY AFTER DILUTION to replenish electrolytes. The preparations contain either 2.92 or 5.84 g of sodium chloride (50 or 100 mEq each of Na+ and Cl¯) in Water for Injection, USP. The solution contains no bacteriostat, antimicrobial agent or added buffer; pH 4.8 (4.5 to 7.0). May contain hydrochloric acid for pH adjustment. The osmolar concentration is 5 mOsmol/mL (calc.); specific gravity is 1.10.

Sodium Chloride, USP is chemically designated NaCl, a white crystalline compound freely soluble in water.

The semi-rigid material used for the plastic vials is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The container requires no vapor barrier to maintain the proper drug concentration.
Alzheimer's disease (AD) is a devastating and increasingly frequent neurological disorder whose onset is strongly correlated with advanced age. Between 2000 and 2017 deaths from AD have increased 145%, and AD has become the 6th leading cause of death in the USA. Unfortunately, in spite of immense research and clinical efforts spanning several decades, cures have been elusive. This has prompted searches for new mechanisms of disease and new targets of therapy. One such direction is inflammation: aging and many age-associated diseases are believed to be causally linked with a chronic inflammatory state. The brain is no exception, and the presence of inflammation in the AD brain establishes an environment that is hostile for the function and survival of neurons. While it is not yet clear whether inflammation is the root cause of AD, it is increasingly believed that alleviating these inflammatory processes might slow down the progression of the disease. This research study will test to determine if the inflammatory state can be alleviated with a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). NRTIs were developed to treat Acquired Immune Deficiency Syndrome (AIDS) caused by infection with Human Immunodeficiency Virus (HIV). Investigators hypothesize that NRTI drugs, by inhibiting neuroinflammation, may be effective in the treatment of AD. The primary goal of this trial will be to assess safety and tolerability of Emtriva in a geriatric population of individuals diagnosed with mild cognitive impairment or early AD.

This study will be conducted in subjects with mild to moderate Alzheimer's disease (AD), including subjects with mild cognitive impairment (MCI). Subjects must be positive for amyloid pathology. Subjects must be 50 to 85 years old, and apart from the clinical diagnosis of early AD, in good health as determined by the Investigator based on their medical history. Participants must be HIV/HBV negative and pass all the screening assessments based on the inclusion/exclusion criteria.
The invention provides an image processing device and an ophthalmic device having the same. The image processing apparatus has a 1 st image input section for inputting a 1 st captured image obtained by capturing a specific portion of an eye to be inspected, a 2 nd image input section, and a display section; the 2 nd image input unit is used for inputting a 2 nd shooting image obtained by shooting a specific part of the eye to be detected; the display unit displays a composite image obtained by combining the 1 st captured image and the 2 nd captured image. The composite image is divided into at least a 1 st region and a 2 nd region by a 1 st dividing line. At least a part of the 1 st captured image, that is, a part corresponding to the 1 st region in the specific region is displayed in the 1 st region. At least a part of the 2 nd shot image, that is, a part corresponding to the 2 nd region in the specific region is displayed in the 2 nd region. Accordingly, a plurality of images acquired from the same portion of the eye to be inspected are easily compared and details are easily confirmed.
PCT No. PCT/EP92/01072 Sec. 371 Date May 9, 1994 Sec. 102(e) Date May 9, 1994 PCT Filed Apr. 15, 1992 PCT Pub. No. WO92/21033 PCT Pub. Date Nov. 26, 1992The present invention concerns a method for the determination of allele-specific peptide motifs on molecules of the major histocompatibility complex (MHC) of classes I and II as well as the peptide motifs which are obtainable by the method according to the invention. In addition the use of the peptide motifs according to the invention for the production of a diagnostic or therapeutic agent is disclosed.
The invention discloses a foot bath health-care traditional Chinese medicine treating a summer heat-dampness cold and relates to the field of traditional Chinese medicines. The traditional Chinese medicine is prepared from 10-15 g of rhizomes of Chinese atractylode, 10-12 g of orange peel, 8-10 g of forsythia, 8-10 g of honeysuckle flowers, 6-8 g of radix angelicae dahuricae, 8-10 g of perilla frutescens, 8-10 g of fresh ginger and 8-10 g of liquorice. By means of many years of practiced medicine experience analysis of an inventor, the summer heat-dampness cold should be treated with relieving heat, clearing dampness and relieving exterior symptoms as the main principle. According to the formula of the traditional Chinese medicine, heat relieving and dampness clearing are achieved through a foot bath method. A patient can fill a prescription by himself/herself to prepare a foot bath medicine bag according to the formula of the traditional Chinese medicine. The summer heat-dampness cold can be totally cured through one-two treatment courses, and the effects of preventing colds and building bodies can be achieved when the traditional Chinese medicine is taken for a long time.
The COVID-19 pandemic exposes our front-line staff to unnecessary risks in interacting with COVID-19 affected patients. Current care of pregnant women who have uncontrolled/unmonitored hypertension involves multiple visits to obstetric units for blood pressure checks. These visits put the women at risk of contracting or transmitting SARS-CoV-2 by bringing them into hospitals for checks which could otherwise be done remotely. Up to 20% of pregnant women will experience a hypertensive episode during pregnancy or the postpartum period. Uncontrolled or unmonitored hypertension in pregnancy may be associated with significant maternal and fetal morbidity and mortality including pre-eclampsia, stroke and stillbirth. The current management of suspected hypertension in pregnancy involves prolonged admission to hospital for BP monitoring or multiple visits to day assessment units or primary care physicians. All of these increase the risk of contracting or transmitting SARS-CoV-2. In addition, pregnant women with COVID-19 who are receiving inpatient care also require regular BP monitoring increasing the exposure risk for staff of contracting SARS-CoV-2. Pregnant women not attending GPs or hospitals for BP monitoring out of fear of contracting COVID-19 drastically increase their risk of suffering adverse effects from undiagnosed or uncontrolled hypertension. The ideal solution would be to facilitate inpatient or outpatient monitoring with reduced face to face contact between staff and infected patients. This would ensure a safer experience for all by reducing the risk of contracting SARS-CoV-2 while safely offering remote BP monitoring. LEANBH offers this safe alternative to direct hospital contact for pregnant women and staff by providing ambulatory automated self BP monitoring using the LEANBH integrated platform. This proposal will deliver immediate ambulatory BP self-monitoring performed remotely without need for direct physical contact, minimising risk of exposure to SARS-CoV-2 for staff and pregnant women.
Hearing loss is a major disability in everyday life and therapeutic interventions to protect hearing would benefit a large portion of the world population. Here we found that mice devoid of the protein kinase suppressor of RAS 1 (KSR1) in their tissues (germline KO mice) exhibit resistance to both cisplatin- and noise-induced permanent hearing loss compared with their wild-type KSR1 littermates. KSR1 is a scaffold protein that brings in proximity the mitogen-activated protein kinase (MAPK) proteins BRAF, MEK1/2 and ERK1/2 and assists in their activation through a phosphorylation cascade induced by both cisplatin and noise insults in the cochlear cells. KSR1, BRAF, MEK1/2, and ERK1/2 are all ubiquitously expressed in the cochlea. Deleting the KSR1 protein tempered down the MAPK phosphorylation cascade in the cochlear cells following both cisplatin and noise insults and conferred hearing protection of up to 30 dB SPL in three tested frequencies in male and female mice. Treatment with dabrafenib, an FDA-approved oral BRAF inhibitor, protected male and female KSR1 wild-type mice from both cisplatin- and noise-induced hearing loss. Dabrafenib treatment did not enhance the protection of KO KSR1 mice, providing evidence dabrafenib works primarily through the MAPK pathway. Thus, either elimination of the KSR1 gene expression or drug inhibition of the MAPK cellular pathway in mice resulted in profound protection from both cisplatin- and noise-induced hearing loss. Inhibition of the MAPK pathway, a cellular pathway that responds to damage in the cochlear cells, can prove a valuable strategy to protect and treat hearing loss.
Ozanimod single doses of 0.46 mg (1 x 0.46 mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
The invention discloses a tea plant hollow hard capsule and a preparation method and application thereof. The tea plant hollow hard capsule is prepared from the following ingredients (by weight): 50-70% of tea leaching liquor, 15-35% of modified tea fiber, 7.5-12.0% of carboxymethyl cellulose (CMC), 0-5% of carrageenan, 0-8% of agar and 0.3-1.5% of a plasticizer. The product has a certain pharmacological activity and health-care function, and biological effect of the content drug is further enhanced. Processing can be carried out with existing gelatin capsule equipment without greatly changing original machining process and technological parameters, utilization rate of equipment is raised, and production cost is remarkably reduced. The raw materials are easily available, and cost is low. There is basically no discharge of pollutants during the production process. According to the invention, industrial production is easy to realize.
Despite extensive efforts, malnutrition persists as a critical public health concern, particularly in developing nations like Ethiopia. Concurrent occurrence of wasting and stunting poses severe consequences. Analyzing trends and factors contributing to this double burden is vital for evaluating and enhancing existing nutritional programs. Additionally, understanding the spatial distribution of malnutrition is crucial for targeted resource allocation, expediting progress towards optimal child growth. A 20-year trend and spatial analysis was conducted among 27,138 weighted samples of under-five children using EDHS (2000-2019). The data extraction was conducted between October 1 and November 1, 2023. STATA 18, ArcGIS Pro, and Sat Scan 9.6 were used for analysis. A logit-based multivariate decomposition analysis was used to identify contributing factors for the change in the double burden of wasting and stunting in the past 20 years. The statistical significance was declared at a P-value < 0.05. The double burden of wasting and stunting had shown a decline from 8.42% in 2000 to 3.31% in 2019. There is a clustered distribution of wasting and stunting (Moran's I = 0.0712, p-value = 0.0290). Significant clustering is detected in the Somali, Afar, and Tigray regions. Among the changes in the effect of the characteristics (coefficient), maternal education level [β = -0.0012, 95% CI -0.0021, -0.0006], wealth level [β = -0.0049, 95% CI -0.0223, -0.0014], family size [β = -0.0014, 95% CI -0.0132, -0.0009] and media access [β = -0.0027, 95% CI -0.0039, -0.0014] were found to be significant contributors to the reduction of the double burden of wasting and stunting over the past 20 years. Despite the significant progress observed in the past 20 years, the problem still requires urgent attention. Thus, improving maternal education and household wealth levels is crucial. Furthermore, enhancing access to and utilization of family planning services and media coverage will help alleviate the burden and end malnutrition. Additionally, deploying additional resources in hotspot areas is also recommended.
The invention discloses a hawthorne leaf extract chewable tablet and a preparation method thereof, belonging to the medical technical field of medicines, and relating to functional food processing. The hawthorne leaf extract chewable tablet comprises treating effective dose of main drug, i.e. hawthorne leaf extract and auxiliary materials, wherein, the treating effective dose of main drug, i.e. hawthorne leaf extract is 6-60% of total weight of the prescription, and the general flavone content is more than 80.0%; the remaining auxiliary material is medicinally-used excipient which comprises filler, disintegrating agent, dispersing agent, lubricating agent and flavoring agent. The preparation method comprises the following steps: carrying out micronization processing on the main drug and parts of auxiliary materials to obtain fusant superfine powder the rain diameter of which is 200-300 meshes; and fusing with polyethylene glycol 6000 to obtain solid dispersing powder to be evenly mixed with other auxiliary materials through tabletting to prepare the finished product. The product of the invention is stable, has exact curative effect, good flavor, convenient carrying and good distribution after being taken by chewing, high biology utilization, convenient taking by chewing, is beneficial for absorption, and is more suitable for the patients having swallow obstacle and inconvenience for water taking. The production process of the invention has strong operability, is simple and fast, and is suitable for industrial production.
OBJECTIVES: I. Determine whether prophylactic use of pilocarpine can shelter unstimulated and stimulated whole salivary flow in patients with head and neck cancer. II. Determine whether prophylactic use of pilocarpine can moderate xerostomia in these patients. III. Determine whether prophylactic use of pilocarpine can reduce the grade and duration of radiation induced mucositis in these patients. IV. Evaluate quality of life outcomes between patients receiving pilocarpine versus placebo. V. Evaluate the impact of xerostomia on patients receiving irradiation to the head and neck.

OUTLINE: This is a randomized, double blind study. Patients receive a central axis midplane dose of radiotherapy five days per week over 6 to 7 weeks. Oral pilocarpine or placebo is administered beginning 3 days prior to radiotherapy, one tablet four times per day for three months. A tablet will be taken 45-60 minutes before radiotherapy. After three months, and after a 3-4 day rest period, all patients receive non blinded pilocarpine for an additional three month period. Patients are followed at weeks 4, 13, and 26 after the start of radiotherapy.

PROJECTED ACCRUAL: A total of 244 patients will be accrued (122 per treatment arm).